Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.
Home
OCARINA I and II: Results and implementation in Newcastle

Discover insights from Dr. Martin Duddy's presentation on the OCREVUS SC Injection. This video offers an overview of the OCARINA I and OCARINA II clinical trials, explores the SC formulation, and examines its impact on MS services and patients in Newcastle.
If you would like support with training, reach out to a member of our team.

References:

  1. OCREVUS IV Summary of Product Characteristics
    2. OCREVUS SC Summary of Product Characteristics
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.